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A Randomized Controlled Trial of
Cognitive Behavioral Therapy for
Adherence and Depression (CBT-
AD) in Patients With Uncontrolled
Type 2 Diabetes
OBJECTIVE
To test cognitive behavioral therapy for adherence and depression (CBT-AD) in
type 2 diabetes. We hypothesized that CBT-AD would improve adherence; de-
pression; and, secondarily, hemoglobin A1c (A1C).
RESEARCH DESIGN AND METHODS
Eighty-seven adults with unipolar depression and uncontrolled type 2 diabetes
received enhanced treatment as usual (ETAU), including medication adherence,
self-monitoring of blood glucose (SMBG), and lifestyle counseling; a provider
letter documented psychiatric diagnoses. Those randomized to the intervention
arm also received 9–11 sessions of CBT-AD.
RESULTS
Immediately after acute treatment (4months), adjusting for baseline, CBT-AD had
20.7 percentage points greater oral medication adherence on electronic pill cap
(95% CI 231.14 to 210.22, P = 0.000); 30.2 percentage points greater SMBG
adherence through glucometer downloads (95% CI242.95 to217.37, P = 0.000);
6.44 points lower depression scores on the Montgomery-Asberg Depression
Rating Scale (95% CI 2.33–10.56, P = 0.002); 0.74 points lower on the Clinical Global
Impression (95% CI 0.16–1.32, P = 0.01); and 0.72 units lower A1C (95% CI 0.29–
1.15, P = 0.001) relative to ETAU. Analyses of 4-, 8-, and 12-month follow-up time
points indicated that CBT-AD maintained 24.3 percentage points higher medica-
tion adherence (95% CI238.2 to210.3, P = 0.001); 16.9 percentage points greater
SMBG adherence (95% CI233.3 to20.5, P = 0.043); and 0.63 units lower A1C (95%
CI 0.06–1.2, P = 0.03) after acute treatment ended. For depression, therewas some
evidence of continued improvement posttreatment, but no between-group
differences.
CONCLUSIONS
CBT-AD is an effective intervention for adherence, depression, and glycemic
control, with enduring and clinically meaningful beneﬁts for diabetes self-
management and glycemic control in adults with type 2 diabetes and depression.
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Despite clear evidence linking glycemic
control and risk for complications (1)
;50% of adults with diabetes achieve
glycemic control targets (A1C,7%) (2).
Patient nonadherence to medications
prescribed to treat diabetes is common
(3) and clearly related to poor glycemic
control, risk for hospitalization, and
mortality (4). Clinical depression is
highly prevalent in diabetes, being up to
two times more common among
patients with diabetes than those
without (5). Depression in diabetes is
not only distressing in and of itself but
also consistently associated with poor
adherence to self-care behaviors (6),
worse glycemic control (7), complications
(8–10), and mortality (11).
Although a few trials have tested the
efﬁcacy of treatments for depression in
adults with diabetes with generally
positive effects on depression, effects
on health outcomes such as glycemic
control and adherence are, at best,
mixed (12). An early small trial of
cognitive behavioral therapy (CBT)
demonstrated an improvement in
glycemic control (13), but subsequent
larger trials of collaborative care have
failed to impact glycemic control (14,15)
or self-care and medication adherence
(16). Accordingly, treating depression
alone may not result in changes in health
behaviors or outcomes; hence, an
integrative approach may be necessary.
Adapting an approach used successfully
in adults with HIV/AIDS (17,18), we
integrated the treatment of depression
and nonadherence (19–22) using CBT
intervention strategies. The objective of
the current study was to test, in a two-
arm randomized controlled trial, CBT for
adherence and depression (CBT-AD)
combined with a series of diabetes self-
management and adherence
interventions, which we call enhanced
treatment as usual (ETAU), versus ETAU
alone in patients with uncontrolled
type 2 diabetes and depression. We
had two major hypotheses. First, we
hypothesized that patients assigned to
CBT-AD would have better adherence,
decreased depression, and improved
glucose control than those assigned to
ETAU at immediately posttreatment
(4 months). Second, we hypothesized
that observed posttreatment between-
group differences in these outcomes
would be sustained over 8- and 12-month
follow-up.
RESEARCH DESIGN AND METHODS
Design and Procedures
This was a 12-month single-blind
randomized trial. All participants had
ETAU. Accordingly, theymet once with a
nurse educator to set goals for self-
monitoring blood glucose (SMBG), twice
with a dietitian to set individualized diet
and physical activity goals, and once
with an adherence counselor to help
with these self-management goals.
There were two arms: 1) CBT-AD plus
ETAU and 2) ETAU alone. Assessments
were at baseline and 4 (immediately
posttreatment), 8, and 12 months and
took place at Massachusetts General
Hospital (MGH) (Diabetes Center,
Behavioral Medicine Service, and/or
Clinical Research Program, Boston, MA).
The period of recruitment was June
2007 to March 2011, with 1-year follow-
up lasting until March 2012.
All procedures were reviewed and
approved by the Institutional Review
Board at MGH. All participants
completed an informed consent process
with a study clinician, including signing
an informed consent form.
Participants
Eighty-seven adults between the ages of
18 and 70 with suboptimally controlled
type 2 diabetes (physician deﬁned as
A1C .7% [53 mmol/mol]) despite
treatment with an oral hypoglycemic
and who also met DSM-IV (23) criteria
for depression (66 current major
depressive episode, 11 current
dysthymic disorder, 10 major
depression in partial remission and
prescribed antidepressant treatment)
were enrolled. Antidepressants for
depression, oral hypoglycemic
medications, and insulin all needed to
be stable for 2 months. The Mini
International Neuropsychiatric
Inventory (24) was used to establish
baseline psychiatric diagnoses. The
assessment of depression during
baseline was conducted by a study
clinician (master- or doctoral-level
psychologist trained through audiotape
supervision in the treatment and
assessment protocols). Other
treatments for depression, such as
medications, were allowed to be
continued or started by usual care
providers, if indicated. If at any visit
treatment for depression beyond what
the study provided was clinically
indicated or if self-report depression
scores increased by 25% compared with
the average of their past two scores,
participants were given appropriate
referrals (e.g., additional therapy,
medication evaluation) and continued
to be followed per the assessment
schedule. Participants who experienced
severe depression (i.e., requiring
intensive treatment such as
hospitalization) were dropped from the
study. Participants who had active
untreated major mental illness (e.g.,
untreated psychosis), bipolar disorder,
eating disorder, mental retardation,
dementia, or active suicidality; were
unable or unwilling to provide informed
consent; or had a history of or were
undergoing current CBT for depression
were excluded.
Interventions
ETAU (All Participants)
Provider Letter and Monitoring of
Depression. After the baseline
assessment, a letter was sent to each
patient’s health-care provider regarding
any psychiatric diagnoses for which the
patient met criteria. The letter stated
that participation in the study should
not alter the provider’s normal course
of assessment or treatment for these
conditions. At follow-up assessments, if
clinically indicated, referrals for
depression treatment were also
provided. Referrals were made if the
participant’s self-reported depression
scores increased by 25% compared with
the average of the prior two and were
also determined on a case-by-case
basis, including but not limited to
situations such as suicidal ideation.
Nurse and Dietitian Visits. Before
randomization, the nurse diabetes
educator met with each patient for
diabetes self-management education
and counseling. The goal of these visits
was to establish tailored goals for
diabetes self-care, including medication
adherence (for both oral medications
and insulin), glucose monitoring,
exercise, and foot care. The dietitian
conducted a nutritional assessment and
then set two individualized nutrition
goals and one activity goal that were
626 CBT-AD in Type 2 Diabetes and Depression Diabetes Care Volume 37, March 2014
selected based on the likelihood of
impacting glucose control and each
participant’s self-conﬁdence in his or
her ability to achieve them. These
activities were evaluated and revised as
necessary at the second visit after
randomization.
Adherence Counseling. All participants
had one session of Life-Steps (25,26), a
stand-alone CBT intervention designed
to improve adherence to medical
recommendations and individualized
diabetes self-management goals set by
the dietitian and nurse. In this
intervention, after brief discussion
about patient-generated reasons for
engaging in treatment, 11 cognitive and
behavioral steps to adherence are
discussed (e.g., setting a daily schedule,
having reminder cues for medications,
managing getting to appointments), and
the interventionist and patient
generate a plan and backup plan for
each (see Supplementary Data).
CBT-AD
The intervention group then
participated in CBT-AD delivered across
9–12 sessions, with the Life-Steps
intervention delivered as session 1. For
additional details, see the
Supplementary Data and/or published
treatment manuals (19,20). The
subsequent modules included 1)
introducing the patient to the nature of
CBT and motivational interviewing for
behavior change (approximately one
session); 2) increasing pleasurable
activities and mood monitoring
(approximately one session); 3) thought
monitoring and cognitive restructuring
(adaptive thinking) (approximately ﬁve
sessions); 4) problem-solving as a skill to
aid in decision-making processes,
particularly those related to diabetes
self-care (approximately two sessions);
and 5) relaxation training
(approximately two sessions). The
therapist and participant were able to
structure the number of sessions spent
on each module to meet the
participant’s individual needs. For all
modules, participants were encouraged
to apply these skills generally, but they
were linked to diabetes self-care
whenever possible. Participants were
offered up to two booster sessions,
which usually happened at the time of
the 8- and 12-month follow-up
assessments. For additional details, see
the Supplementary Data and/or
published treatment manuals (19,20).
Outcomes
Medication Adherence
Each patient was given a medication
event monitoring system (MEMS;
AARDEX Inc.) electronic pill cap, which
ﬁts on a medication bottle and registers
each time the patient’s medication
bottle is opened. This system allowed us
to calculate the percentage of doses
taken. A corrected score was used if
participants could recall times when
they took pills but did not use the bottle
(17,18,27–29). Participants informed
study staff of changes to medications
during the course of the study, and this
was accounted for in the calculation of
these adherence scores.
Adherence to Glucose Monitoring
One Touch Ultra meters (LifeScan, Inc.)
for daily glucose control also provided
frequency of self-monitoring, which
compared with the individualized goals
from the nurse visits, also yielded a
percentage (30,31) adherence score.
The Montgomery-Asberg Depression
Rating Scale
The Montgomery-Asberg Depression
Rating Scale (MADRS) (32) is a
structured, validated, 10-item interview
that was completed by the blinded
assessor.
Clinical Global Impression
The blinded assessor also used the
Clinical Global Impression (CGI) (1 = not
ill, 7 = extremely ill) (33), a single-item,
valid, and reliable measure of the
severity of global impairment and
distress related to depression.
Assessment of Diabetes Control
Assessment of diabetes control was
determined by measurement of A1C, at
the MGH laboratory, one of the
reference laboratories for the National
Glycohemoglobin Standardization
Program (34,35), using a Bio-Rad Variant
II Turbo (normal range 3.8–6.4% [18–46
mmol/mol]). No point-of-care A1C tests
were used.
Sample Size
The study was powered for adherence
and depression outcomes according to
our initial work in HIV (17), which had
effect sizes in excess of 1.0 for these
outcomes. The recruitment goal was
100 completers, which would have
allowed for an excess of 95% power to
detect an effect size of 1.0 for
adherence and depression with a
general linear model (GLM) ANOVA
approach for the posttreatment effect.
We experienced slower-than-
anticipated recruitment but still had
sufﬁcient power to conduct the analyses
with 87 participants.
Randomization
We stratiﬁed randomization based on
prescription of medication (oral
medication, insulin, or both), sex, and
CGI score ($3 cutoff) in blocks of four.
The randomization sequence was
generated by the data manager;
participants were assigned to a study
arm by the research assistant. Study
interventionists conducted the
enrollment visits.
Blinding
Participants, study assessors,
interventionists, and dietitians were
blinded to study assignment during the
baseline visit, the three nurse/dietitian
visits, and the adherence counseling
visit.
Statistical Methods
The two sets of analyses corresponded
to the two study hypotheses: 1) CBT-AD
will result in superior adherence,
depression, and glucose control, and
2) the beneﬁts will be maintained over
8months. All analyses used SPSS version
19 or 20 statistical software and
followed intention-to-treat principles.
For signiﬁcant differences, parameter
estimates (B) are in the units of the
measure that best describe the clinical
implication of the results.
The ﬁrst set of analyses corresponds to
the ﬁrst hypothesis that the CBT-AD
condition would have superior
outcomes at the end of acute treatment.
Accordingly, we evaluated between-
group differences at the 4-month
assessment (i.e., immediately
posttreatment), controlling for baseline
scores. To allow for intention-to-treat
principles, we used GLMs with multiple
imputation to provide conservative
estimates for missing data. (Completer
analyses revealed a similar pattern of
results, although with stronger P values
and larger parameter estimates.) For
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the ﬁrst set of analyses, we
hypothesized that the CBT-AD condition
would have lower depression, higher
adherence, and lower A1C than the
ETAU condition.
The second set of analyses corresponds
to the second hypothesis that thosewho
participated in the treatment would
maintain their beneﬁt. Accordingly, we
evaluated the follow-up data by mixed-
effects modeling with the 4-, 8-, and
12-month data. These models did not
include baseline values. They contained
a term for treatment condition, which
measured the difference between the
two conditions over the entire follow-up
period; a term for time, whichmeasured
the extent to which the values
decreased or increased over time
averaged over both conditions; and an
interaction term, which measured
whether the change with time, after
acute treatment was discontinued, was
different in the two treatments over the
follow-up period. The purpose of these
analyses was to examine whether there
was an effect for the treatment
condition term. Accordingly, we
hypothesized that there would be a
signiﬁcant main effect for treatment
condition such that after acute
treatment discontinuation, the CBT-AD
condition would maintain lower
depression, higher adherence, and
lower A1C than the comparison
condition. Additionally, we
hypothesized that there would not be
an effect for time after acute treatment
discontinuation, improvements in the
CBT condition would not wane, and the
comparison condition would not make
changes after the 4-month assessment.
Finally, we hypothesized that there
would not be a signiﬁcant effect for the
interaction of time by condition during
this follow-up period such that both
groups would maintain scores similar to
those at the 4-month assessment.
RESULTS
Participant Characteristics and Flow
A CONSORT (Consolidated Standards of
Reporting Trials) diagram of participant
ﬂow is shown in Fig. 1. Table 1 lists the
baseline characteristics for those
randomized. None of the demographic
or outcome data differed by treatment
arm. For the posttreatment outcome,
retention was 90%, and 83% of
participants returned for either the 8- or
12-month follow-up. Three participants
(all in ETAU) were dropped because of
severe depression requiring more-
intensive treatment (two at 4 months
and one at 8 months). There were no
study-related adverse events.
Posttreatment (Acute/4-Month)
Outcomes
Adherence
At posttreatment, controlling for
baseline, the CBT-AD arm had 20.7
percentage points higher adherence to
medications as assessed by electronic
pill cap (95% CI 231.14 to 210.22,
P = 0.000) and 30.2 percentage points
higher electronically assessed 2-week
SMBG (95% CI 242.95 to 217.37, P =
0.000) than the ETAU arm (Table 2).
Depression
Controlling for baseline, the CBT-AD arm
had 6.22 lower depression scores on the
MADRS than the ETAU arm (95% CI
2.33–10.56, P = 0.002) and 0.74 lower
ratings on the CGI (95% CI 0.16–1.32, P =
0.01), where lower scores indicate less
depression on both scales (Table 2).
Diabetes Control
Controlling for baseline, the CBT-AD arm
had superior glycemic control as
indicated by a 0.72 difference in A1C
compared with the ETAU group (95% CI
0.29–1.15, P 5 0.001).
Follow-up/Maintenance of Gains
Adherence
For medication adherence, a signiﬁcant
main effect for study arm indicated that
the CBT-AD arm maintained 24.3
percentage points higher medication
adherence than the ETAU arm during
the follow-up period (95% CI 238.2 to
210.3, P = 0.001) (Table 3). The main
effect for time was not signiﬁcant (P =
0.14), indicating that adherence gains
did not signiﬁcantly decline or improve
from the time of treatment
discontinuation to the follow-ups. The
interaction of time by study armwas not
signiﬁcant (P = 0.09), indicating that the
nonsigniﬁcant main effect for time over
the follow-up period was not different
by study arm; after acute treatment
ended, both groups did not differ at
months 8 or 12 from the scores they had
right after the acute treatment ended
(i.e., month 4).
For adherence to glucose monitoring
goals, a signiﬁcant main effect for study
arm indicated that the CBT-AD arm
maintained 16.9 percentage points
better glucose monitoring adherence
than the ETAU arm during the follow-up
period (95% CI 233.3 to 20.5, P =
0.043). A signiﬁcant effect for time
(P = 0.001), however, indicated some
decline over follow-up, with scores at
month 8 being 12.5 percentage points
lower than at month 4 (95% CI 5.9–19.1,
P = 0.001) and 9.1 percentage points
lower at month 12 than at month 4
(95% CI 2.7–15.5, P = 0.006), without
signiﬁcant differences between 8 and
12 months (B = 23.4, 95% CI 29.5 to
2.7, P = 0.27). The interaction effect
between time by study arm was not
signiﬁcant (P = 0.24), indicating that
these declines over time after acute
treatment ended (at month 4) did not
differ by study arm (i.e., both groups
had decreased adherence to SMBG
goals over time, but the CBT-AD arm
remained superior).
Depression
For the MADRS, there were no
signiﬁcant effects for study arm (P =
0.16) during the follow-up period. There
was a trend, however, toward continued
improvement over follow-up for both
study arms (P = 0.06). Depression scores
were 2.4 points lower at month 12 than
at month 8 (95% CI 0.23–4.5, P = 0.03)
and 2.5 points lower at month 12 than at
month 4 (95% CI 0.10–4.8, P = 0.04),
without signiﬁcant differences between
4 and 8months (B = 0.10, 95% CI22.1 to
2.3, P = 0.9). The interaction was not
signiﬁcant, indicating that these time
point improvements did not differ by
study arm (P = 0.22). Accordingly,
although the trend for improvement
occurred in both conditions, the better
scores in the CBT-AD condition were not
sustained after acute treatment
discontinuation.
For the CGI, there was an absence of
main effects for study arm (P = 0.10)
during the follow-up period. There also
were not effects for time (P = 0.28),
indicating that scores did not
signiﬁcantly decline or improve after the
treatment ended. The interaction effect
was also not signiﬁcant (P = 0.40),
indicating that the nonsigniﬁcant effects
for time did not differ by study arm
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during follow-up. Accordingly, although
the CBT-AD condition did not have
signiﬁcantly worsening of scores after
acute treatment discontinuation, the
superiority over the control condition
was no longer signiﬁcant in the follow-
up period.
Diabetes Control
The CBT-AD arm maintained superior
glycemic control compared with the
ETAU arm, as indicated by 0.63 lower
A1C values (95% CI 0.06–1.2, P = 0.03),
over the follow-up. The main effects for
time were not signiﬁcant (P = 0.53),
indicating maintenance of gains from
the time of treatment discontinuation
to month 8 or month 12. The interaction
effect was not signiﬁcant (P = 0.49),
indicating that the nonsigniﬁcant effects
for time did not differ by study arm
during follow-up. Accordingly, the
Figure 1—Participant ﬂow diagram. PI, principal investigator.
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CBT-AD condition retained superior A1C
scores during the follow-up period.
CONCLUSIONS
After completing 4 months of CBT-AD,
patients with uncontrolled type 2
diabetes and depression had lower A1C
(0.72-unit reduction), 21 percentage
points better medication adherence,
and 30 percentage points better
adherence to SMBG than patients
assigned to ETAU. For glycemic control,
the effect of the intervention was
comparable to the addition of a weak
hypoglycemic medication (36). These
gains were maintained over the 8
months of follow-up (after the acute
delivery of intervention), with between-
group differences evident for glycemia
and the two adherence outcomes.
For depression, right after acute
treatment ended at the 4-month
assessment, those who received CBT-AD
had scores that were 6.44 points better
on theMADRS and 0.74 points better on
the CGI for depression than the ETAU
participants, indicating signiﬁcantly
lower levels of depression in the CBT-AD
group. Although mean scores over time
revealed continued improvement for
both conditions, there was a lack of
between-group difference in the
postintervention follow-up period. At
least two possible conclusions can be
drawn from these data. The ﬁrst is that
the effects of CBT-AD on depression
were not robust enough to be
maintained over time relative to alerting
providers of depression diagnoses.
However, depression scores in the
intervention condition did not worsen
during the follow-up, and data showed a
trend for continued improvement in
scores on the MADRS. Furthermore,
scores did not change differently across
the two conditions during the follow-up.
Therefore, the second possible
conclusion is that this pattern of results
could be related to the study design.
Whenever clinically indicated,
participants were referred for further
care for depression. At baseline,
referring primary care providers were
informed that depression had been
detected in ETAU participants. Despite
this, there were signiﬁcant group
differences on both depression
outcomes. At follow-up, study staff (not
primary care providers) directly referred
ETAU participants with clinically
signiﬁcant depression for treatment
outside the study. Additionally,
participants who were severely
depressed (n = 3, all in the ETAU group)
were dropped from the study at month
4 (or any other time point, but it only
happened at month 4) for ethical
reasons and referred to more-intensive
care. This ethical consideration may
have affected the distribution of scores
in the ETAU group, with the most severe
scores for depression no longer being
present. If it were not for this needed
design, we may have seen stronger
effects for depression. Themaintenance
of clinically signiﬁcant effects on
diabetes self-management and glycemic
control over the follow-up, despite the
lack of maintenance of the depression
effects, suggests some degree of
independence between these
outcomes. This may also explain why
previous trials that were successful in
treating depression in diabetes failed to
demonstrate corresponding beneﬁts for
self-management or glycemic control
(14–16).
Table 1—Baseline demographics and outcomes by study condition
CBT-AD (n = 45) ETAU (n = 42)
Sex
Male 22 (48.9) 22 (52.4)
Female 23 (51.1) 20 (47.6)
Age (years) 55.44 (8.72) 58.31 (7.41)
Race
White 41 (91.1) 34 (81.0)
African American 3 (6.7) 4 (9.5)
Asian 0 (0.0) 1 (2.4)
Other 0 (0.0) 2 (4.8)
Native American 2 (4.44) 0 (0.0)
Ethnicity
Not Hispanic or Latino 45 (100.0) 39 (92.9)
Hispanic or Latino 0 (0.0) 3 (7.1)
Insulin status
Oral medications only 21 (46.7) 18 (42.9)
Insulin only 8 (17.8) 7 (16.7)
Both oral medications and insulin 16 (35.6) 17 (40.5)
Clinical and adherence characteristics (unadjusted)
Medication adherence (%) 76.64 (25.99) 85.66 (24.62)
Glucose monitoring 54.27 (35.63) 67.07 (32.20)
Depression scale 25.60 (8.99) 23.31 (7.20)
MADRS
CGI 4.42 (1.29) 3.98 (1.09)
A1C
% 8.81 (1.78) 8.74 (1.41)
mmol/mol 73 72
Data are n (%) or mean (SD) unless otherwise indicated.
Table 2—Adjusted posttreatment (4-month) outcome scores by treatment arm
CBT-AD ETAU
MEMS 90.37 (3.48) 69.69 (3.72)
Glucose monitoring 79.79 (4.03) 49.63 (4.66)
MADRS 14.22 (1.45) 20.66 (1.52)
CGI 2.44 (0.21) 3.17 (0.20)
A1C
% 7.86 (0.16) 8.58 (0.16)
mmol/mol 62 70
Data are mean (SE) unless otherwise indicated. Scores are adjusted for baseline scores in the
GLM analyses. All mean score differences were signiﬁcantly superior for the CBT-AD condition
compared with ETAU. See Supplementary Data for graphical depiction of these scores.
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One difference between this study and
earlier investigations of treatments for
depression in diabetes (12–16) is that
the current study integrated adherence
counseling into the psychosocial
treatment of depression versus treating
depression without also speciﬁcally
targeting adherence. The rationale for
this integrative approach was based on
the documented association of
depression and poor diabetes treatment
adherence (6) and the failure of
previous trials to consistently impact
glycemic control or diabetes self-
management (12). Since the initiation of
this trial, we are aware of two others
that have taken a similarly integrative
approach. One was successful in
improving depression, medication
adherence, and glycemic control for
patients already prescribed
antidepressants (37), and the second
failed to impact self-management or
medication adherence but did affect
glycemic control and depression (38).
However, the second trial differentially
provided medications for depression,
glycemic control, blood pressure, and
lipids to experimental participants
relative to controls, which may have
accounted for glycemic beneﬁts
observed in the absence of
improvements in self-management (39).
The current results, therefore, add to
the evidence base for the conclusion
that treating depression may be
necessary but not sufﬁcient to improve
diabetes outcomes in depressed adults
with type 2 diabetes. Treating
depression may allow patients to
maximally beneﬁt from adherence/self-
care interventions such as those
provided to both the experimental
intervention and the comparison arms
of the current study. The magnitude of
the present effects suggests that such
an approach could have clinically
meaningful beneﬁts for glycemic
control.
The study results have several
limitations to note. First, the study was
meant to examine whether treating
depression with an evidenced-based
and comprehensive approach would be
superior to ETAU, which included nurse
and dietitian counseling and adherence
counseling. We chose this approach
because CBT is a widely studied
treatment for depression, and well-
designed depression treatment trials in
diabetes had already demonstrated that
depression treatment did not
consistently result in improved glycemic
control or diabetes self-management
(14,15,39). Therefore, we sought to test
an integrative approach in a design that
could evaluate whether a more time-
intensive intervention would have
greater efﬁcacy on a comprehensive set
of depression and diabetes outcomes
relative to less-intensive, but still
signiﬁcant enhancements to usual care.
This design allowed for greater
translation of the ﬁndings to clinical
practice in that there were no artiﬁcial
restrictions on additional treatment in
either arm, and the comparison group
we evaluated more closely represents
models of care that could be
implemented in practice. However, our
design cannot address questions about
the role of increased attention and
nonspeciﬁc support provided as part of
the intervention. Second, theMEMS cap
used for the medication adherence
outcomemay have underestimated true
adherence in that participants could
take pills and not use the cap. To correct
for this, we asked participants at study
visits whether they recalled taking the
pills without using the cap and used a
corrected adherence score (27–29).
Third, the sample was 86%white; hence,
additional study is needed to extend
ﬁndings to racial or ethnic minorities.
Fourth, although brief for
psychotherapy, the treatment was
intensive, and the study design required
participants to meet criteria for a
depressive disorder. Subsequent work
suggests that the relationship between
depression and worse outcomes in
diabetes is incremental and that
patients with subclinical depression
could also beneﬁt from treatment (40).
Finally, we were not able to include use
of antidepressants as a variable in the
analyses because of variability in dose,
type of medicine, timing of any changes,
and lack of measuring adherence.
Including antidepressant use
systematically may have increased the
precision of the estimate of the effect of
the intervention over and above ETAU,
which can include the use of
antidepressants.
In conclusion, given the high prevalence
of depression in patients with diabetes
and the association of depression with
poor adherence and outcomes,
interventions to treat depression and
improve adherence could improve
diabetes care. Overall, these results
suggest that a behavioral intervention
for depression and diabetes treatment
nonadherence (CBT-AD) (19,20) is
effective for managing depression and
treatment nonadherence and improving
glycemic control in depressed adults
with type 2 diabetes.
Table 3—Adjusted follow-up outcome scores by study condition
Month 4 Month 8 Month 12 Signiﬁcance level
CBT-AD ETAU CBT-AD ETAU CBT-AD ETAU Condition Time Interaction
MEMS 91.37 (1.51) 73.99 (5.20) 80.81 (4.37) 73.40 (5.68) 88.63 (2.10) 64.38 (6.75) 0.001 0.14 0.09
Glucose monitoring 79.03 (4.07) 51.08 (5.19) 63.61 (5.63) 41.46 (6.57) 64.40 (5.61) 47.51 (6.11) 0.043 0.001 0.24
MADRS 14.83 (1.79) 20.03 (1.60) 16.62 (1.66) 18.02 (1.98) 13.72 (1.70) 16.21 (1.83) 0.16 0.06 0.22
CGI 2.53 (0.24) 3.08 (0.23) 2.63 (0.25) 2.87 (0.29) 2.22 (0.23) 2.86 (0.26) 0.10 0.28 0.40
A1C 0.03 0.53 0.49
% 7.75 (0.20) 8.57 (0.26) 8.01 (0.22) 8.57 (0.26) 7.93 (0.20) 8.44 (0.24)
mmol/mol 61 70 64 70 63 69
Data aremean (SE) unless otherwise indicated. Scores are adjusted through the use of mixed-effects analyses. See Supplementary Data for graphical
depiction of these scores.
care.diabetesjournals.org Safren and Associates 631
Author Notes
1. Of the 87 participants randomized,
84 had A1C levels of $7.0 (53
mmol/mol). Three participants had
A1C approaching 7.0 on study blood
draw but a self-reported A1C .7.0
(6.8 [51 mmol/mol], 6.9 [52 mmol/
mol], and 6.9 [52 mmol/mol]). These
participants were entered into the
study with a protocol exception
because the study blood draw A1C
values were considered essentially
equivalent to 7.0.
2. Although we originally planned to
also use average blood glucose
values downloaded from
participants’ glucometers as an
additional indicator of glycemic
control, experience with the initial
participants and in the pilot
demonstrated that this procedure
was not feasible because values
depend on timing of monitoring and
whether the participant was fasting.
In light of the burden to participants
and the potential for error of
reporting of fasting/not fasting, we
dropped this outcome in favor of
A1C, which is a superior indicator of
glycemic control over time.
3. We monitored progress on
depression at study visits with the
Center for Epidemiologic Studies
Depression Scale.
4. The full protocol may be accessed by
request to the corresponding author.
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